Moderna secures up to $50 million to develop an Ebola vaccine.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's ...

A top adviser has resigned from the Food and Drug Administration's (FDA) vaccine advisory committee amid concerns about her ...

Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks With Remarkable Resilience. Moderna snapped a four-day losing streak on ...

Investors are seeking more durable growth drivers beyond COVID vaccines as Moderna ⁠cuts costs and works to return to growth in the post-pandemic era, while proving the ⁠long-term commercial viability ...

AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

Oxford University and Moderna launch trials of vaccine that could prevent cancer - The jab targets patients with Lynch ...

The Moderna Innovation and Technology Centre (MITC) at Harwell Science and Innovation Campus. Moderna and the University of Oxford in the UK have been cleared to start human trials of what could be ...

Moderna on Friday posted fourth-quarter revenue that beat estimates, but lost more than expected for the period, as the biotech company continues to slash costs and demand for its Covid vaccine falls.

Moderna (MRNA) is scheduled to report first-quarter earnings on Friday, May 1, before market open, with investors looking for signs of stabilization after a prolonged post-pandemic downturn. The ...

Moderna became famous after it developed one of the leading coronavirus vaccines on the market. But the company's COVID-related work is no longer a major growth driver. Investors have instead been ...